|
|
|
|
|
RigshospitaletOn 26 July 2005, the Company entered into a research collaboration agreement with Rigshospitalet, Denmark, concerning research regarding Topotect for brain metastases. The agreement is expected to be renewed in the near term.Under the research collaboration agreement, Rigshospitalet granted the Company the right to use the laboratory facilities for research and the Company agreed to pay the costs of Ph.D. students who are supervised by employees from the Company. Rigshospitalet is entitled to a royalty of 4 per cent of any income which the Company may generate through Topotect for brain metastases, up to a maximum of DKK 10 million (EUR 1.3 million). “Income” is defined as any licence or upfront payment, milestone payments and royalty payments from licence agreements after deduction of direct costs. If the Company instead were to sell Topotect to a third party, Rigshospitalet would be entitled to 4 per cent of the net purchase sum payable to the Company on such sale, up to a maximum of DKK 10 million (EUR 1.3 million). The Company has the right to conduct research at Rigshospitalet’s facilities and is entitled to any inventions made during such research. However, jointly developed inventions will be shared between Rigshospitalet and the Company unless one party has contributed significantly more than the other party, in which event the rights will be allocated in accordance with the estimated contributions. Disagreements regarding the allocation are to be determined by a patent agent.
http://www.rigshospitalet.dk
|
|
|
About Us
Cancer